Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 339

1.

Racial differences in initial treatment for clinically localized prostate cancer. Results from the prostate cancer outcomes study.

Hoffman RM, Harlan LC, Klabunde CN, Gilliland FD, Stephenson RA, Hunt WC, Potosky AL.

J Gen Intern Med. 2003 Oct;18(10):845-53.

2.

Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study.

Hoffman RM, Gilliland FD, Eley JW, Harlan LC, Stephenson RA, Stanford JL, Albertson PC, Hamilton AS, Hunt WC, Potosky AL.

J Natl Cancer Inst. 2001 Mar 7;93(5):388-95.

3.

Racial treatment trends in localized/regional prostate carcinoma: 1992-1999.

Underwood W 3rd, Jackson J, Wei JT, Dunn R, Baker E, Demonner S, Wood DP.

Cancer. 2005 Feb 1;103(3):538-45.

4.

Trends and black/white differences in treatment for nonmetastatic prostate cancer.

Klabunde CN, Potosky AL, Harlan LC, Kramer BS.

Med Care. 1998 Sep;36(9):1337-48.

PMID:
9749657
5.
6.

Postprostatectomy cancer-free survival of African Americans is similar to non-African Americans after adjustment for baseline cancer severity.

Underwood W 3rd, Wei J, Rubin MA, Montie JE, Resh J, Sanda MG.

Urol Oncol. 2004 Jan-Feb;22(1):20-4.

PMID:
14969799
7.
8.

Racial/Ethnic differences in functional outcomes in the 5 years after diagnosis of localized prostate cancer.

Johnson TK, Gilliland FD, Hoffman RM, Deapen D, Penson DF, Stanford JL, Albertsen PC, Hamilton AS.

J Clin Oncol. 2004 Oct 15;22(20):4193-201.

9.

Predictors of aggressive therapy for nonmetastatic prostate carcinoma in Massachusetts from 1998 to 2002.

Rose AJ, Backus BM, Gershman ST, Santos P, Ash AS, Battaglia TA.

Med Care. 2007 May;45(5):440-7.

PMID:
17446830
10.

Racial differences in mortality among Medicare recipients after treatment for localized prostate cancer.

Godley PA, Schenck AP, Amamoo MA, Schoenbach VJ, Peacock S, Manning M, Symons M, Talcott JA.

J Natl Cancer Inst. 2003 Nov 19;95(22):1702-10.

11.

Is Hispanic race an independent risk factor for pathological stage in patients undergoing radical prostatectomy?

Lam JS, Desai M, Mansukhani MM, Benson MC, Goluboff ET.

J Urol. 2003 Dec;170(6 Pt 1):2288-91.

PMID:
14634398
12.

Factors associated with initial therapy for clinically localized prostate cancer: prostate cancer outcomes study.

Harlan LC, Potosky A, Gilliland FD, Hoffman R, Albertsen PC, Hamilton AS, Eley JW, Stanford JL, Stephenson RA.

J Natl Cancer Inst. 2001 Dec 19;93(24):1864-71.

13.

The association between presentation PSA and race in two sequential time periods in prostate cancer patients seen at a university hospital and its community affiliates.

Pan CC, Lee JS, Chan JL, Sandler HM, Underwood W, McLaughlin PW.

Int J Radiat Oncol Biol Phys. 2003 Dec 1;57(5):1292-6.

PMID:
14630264
14.

Marriage and ethnicity predict treatment in localized prostate carcinoma.

Denberg TD, Beaty BL, Kim FJ, Steiner JF.

Cancer. 2005 May 1;103(9):1819-25.

16.
17.

Racial differences in prostate cancer treatment outcomes: a systematic review.

Peters N, Armstrong K.

Cancer Nurs. 2005 Mar-Apr;28(2):108-18. Review.

PMID:
15815180
18.
19.

Race independently predicts prostate specific antigen testing frequency following a prostate carcinoma diagnosis.

Zeliadt SB, Penson DF, Albertsen PC, Concato J, Etzioni RD.

Cancer. 2003 Aug 1;98(3):496-503.

20.

Clinical features and treatment outcome of Hispanic men with prostate cancer following external beam radiotherapy.

Rosser CJ, Kuban DA, Levy LB, Pettaway CA, Chichakli R, Kamat AM, Sanchez-Ortiz RF, Pisters LL.

J Urol. 2003 Nov;170(5):1856-9.

PMID:
14532792
Items per page

Supplemental Content

Write to the Help Desk